Addex Ends Migraine Prevention Study

Addex Extends Parkinson’s Disease Collaboration with Merck & Co., Inc.

Addex ADX48621 Positive Primate Parkinson’s Data

Addex ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial

Addex Presents ADX10059 PD-LID Data at GPCR Drug Discovery Conference

Addex completes enrollment of first mid-stage clinical GERD trial

Laurent Massuyeau, Head of Business Development, Resigns

Addex’ ADX10059 has potential for Parkinson’s disease levodopa induced dyskinesia (PD-LID)

Addex Pharmaceuticals Reports First Half 2009 Financial Results

Addex First Half 2009 Financial Results Tuesday, July 28